Skip to main content

Human IFN-Alpha All Subtype ELISA Kit, High Sensitivity (TCM)

Hero Region
Product Info

Matrix CompatibilityTissue Culture Media (TCM)
Assay Range1.95 - 125 pg/ml
LLOQ

1.95 pg/ml

Need more sensitivity? Check out our Sample Testing Services

Assay Length20 hours 30 minutes - 24 hours 30 minutes
SpecificityHuman IFN-α

 

The VeriKine-HS Human Interferon Alpha All Subtype TCM ELISA Kit is specifically formulated to detect all human IFN-Alpha subtypes. This kit quantitates all human IFN alpha subtypes in tissue culture media (TCM) using a sandwich immunoassay format. The kit is based on an ELISA with biotinylated-detection antibody and streptavidin-conjugated horseradish peroxidase (HRP). Tetramethyl-benzidine (TMB) is the substrate. The assay is based on the international reference standard for human interferon alpha provided by the National Institutes of Health.

 

*For complex biological matrices such as plasma, healthy sera, and autoimmune disease sera, we recommend our Human IFN-Alpha All Subtype ELISA Kit, High Sensitivity (Cat. No. 41115-1).

Specifications

CVs and Spike Recovery

Inter-Assay: ≤ 10%


Intra-Assay: ≤ 8%


Average Spike Recovery: 105%

Cross-reactivity

Cross-reacts with

  • Cynomolgus/Rhesus IFN-α (13%)

 

No cross-reactivity against

  • Human IFN-β, IFN-γ, or IFN-ω
  • Mouse or Rat IFN-α, IFN-β or IFN-γ
  • Pig IFN-α
  • Bovine IFN-τ

Storage

2-8°C

Expiration Date

One year from the date of manufacture

Shipping Condition

Wet Ice

 

 

Materials Provided

  • Pre-coated microtiter plate
  • Plate Sealers
  • Wash Solution Concentrate
  • Human Interferon Alpha Standard, 10,000 pg/ml
  • Assay Buffer
  • Standard Diluent
  • Antibody Diluent
  • Antibody Concentrate
  • HRP Conjugate Concentrate
  • HRP Diluent
  • TMB Substrate Solution
  • Stop Solution

 

Additional Materials Required (Not Provided)

  • Microtiter plate reader capable of reading a wavelength of 450 nm
  • Plate shaker (recommended shaking capability of 550 rpm)
  • Variable volume microtiter pipettes
  • Adjustable multi-channel pipette (50-300 μl)
  • Reagent reservoirs
  • Wash bottle or plate washing system
  • Distilled or deionized water
  • Serological pipettes (1, 5, 10 or 25 ml)
  • Disposable pipette tips (polypropylene)

Tech Info & Data

Tips, Tools and Troubleshooting:

 

 

SubtypeLLOQ

Representative Human IFN-Alpha All Subtype Detection

α1 (αD)2.06
α2a (αA)1.41
α4a (αM1)2.03
α5 (αG)1.20
α6 (αK)0.82
α7 (αJ1)1.93
α8 (αB2)2.67
α10 (αC)1.98
α14 (αH)3.06
α16 (αWA)2.39
α17 (αI)2.26
α21 (αF)4.96

 

 

Representative Standard Curves of Human IFN-Alpha Subtypes

41135 Standard Curves in Various Matricies

 

Intra-Assay Precision

TC Media Spike Sample123
n202020
Mean (pg/ml)2.3912.9087.16
Standard Deviation0.130.464.58
CV (%)5.43.65.3

 

 

Inter-Assay Precision

TC Media Spike Sample123
n999
Mean (pg/ml)3.2915.1393.69
Standard Deviation0.160.836.07
CV (%)4.95.56.5

 

Intermediate Precision

TC Media Spike Sample123
n999
Mean (pg/ml)3.2915.3094.00
Standard Deviation0.441.757.37
CV (%)13.411.47.8

 

Spike Recovery

TC Media Spike Sample123
n252525
Average Recovery (%)109102104
Range86-14381-12290-120

 

Linearity

41135 Linearity of Dilution
Human IFN-Alpha was spiked into three tissue culture media (RPMI, DMEM and MEM) at 80 pg/ml and then serially diluted with Standard Diluent to assess assay linearity.

 

Parallelism of Endogenous Samples

Parallelism of Endogenous Samples
Five endogenous samples were tested on Cat No. 41135 and assayed in duplicate. Samples were serially diluted in TCM to the 32nd dilution, which still lies within standard curve range. Percent recoveries are 100±20% of the neat value. Cat. No. 41135 has acceptable parallelism. Error bars indicate standard deviation.

 

sIFNAR2 Receptor Interference

sIFNAR2 Receptor Interference
To test whether the soluble IFN Alpha/Beta Receptor 2 (sIFNAR2) receptor interferes with the detection of IFN-Alpha in Cat No. 41135, two concentrations of standard (1.6 ng/ml and 16 ng/ml) were pre-incubated with sIFNAR2 for 1 hour at room temperature, prior to proceeding with the assay. Concentrations were interpolated from assay calibrator. Standard curves preincubated with sIFNAR2 were backfitted against standard curves without sIFNAR2. Error bars indicate standard deviation. (n=2)

 

Endogenous Levels of IFN-Alpha Quantified in Sendai Virus (A549)

Endogenous Levels of IFN-Alpha Quantified in Sendai Virus (A549)
A549 cells were infected with 15 HA units of Sendai Virus (SeV). Supernatants were collected at five time points post infection (2, 6, 24, 48, and 72 hours). Samples were assayed in Cat. No. 41135, Competitor A’s, and Competitor B’s plates; there was no quantification on Competitor B’s plate. 24, 48 and 72 hour time points were prediluted 1:10 in DMEM prior to start of assay for 41135 only. The standard curve and samples were assayed in duplicate. Sample concentrations were interpolated from assay calibrators from each respective vendor. Error bars indicate standard deviation.

 

Endogenous Levels of IFN-Alpha Quantified in Sendai Virus (U937)

Endogenous Levels of IFN-Alpha Quantified in Sendai Virus (U937)
U937 cells were infected with 1.5 HA units of Sendai Virus (SeV). Supernatants were collected at four timepoints post infection (6, 24, 48, and 72 hours). Samples were prediluted to 1:50 final dilution in RPMI prior to start of assay, except for 6 hour timepoint. The standard curve and samples were assayed in duplicate. Sample concentrations were interpolated from assay calibrators from each respective vendor. Error bars indicate standard deviation.

 

Background

 

Interferons (IFNs) are a family of mammalian cytokines initially characterized by their ability to inhibit viral infection. They are synthesized and secreted by most cell types in response to pathogens. In addition to their antiviral properties, IFNs have also been shown to exhibit anti-proliferative, immunomodulatory, and many other activities.

 

In humans, IFN-α refers to a family of proteins comprised of 12 highly homologous protein subtypes (greater than 85% by amino acid sequence), encoded by 13 genes, that exhibit pleiotropic biologic activities. Measuring the levels of the 12 different human IFN-α subtypes is essential for understanding their triggers and subsequent effects on the immune system. The ability to measure all the subtypes may provide an indication of the total IFN-α level.

Citations

9 Citations:

  1. Bulut, O. et al., (2024), "Alendronate Modulates Cytokine Responses in Healthy Young Individuals After BCG Vaccination", Immunol Lett., PMID: 38479480, DOi: 10.1016/j.imlet.2024.106851 (link)
  2. Salzmann, R.J.S. et al., (2024), "Increased type-I interferon level is associated with liver damage and fibrosis in primary sclerosing cholangitis", Hepatol Commun., 8(3):e0380, PIMD: 38358371, DOI: 10.1097/HC9.0000000000000380, (link)
  3. Roring RJ. et al.,  (2024), "MMR vaccination induces trained immunity via functional and metabolic reprogramming of γδ T cells", J. Clin Invest. e170848, PMID: 38290093, DOI: 10.1172/JCI170848 (link)
  4. Heider, A. et al., (2024), "Characteristics of two zoonotic swine influenza A(H1N1) viruses isolated in Germany from diseased patients", International Journal of Medical Microbiology, 314:151609, DOI: 10.1016/j.ijmm.2024.151609 (link)
  5. Ide, M. et al., (2024), "Hepatitis B virus evades the immune system by suppressing the NF-kB signaling pathway with DENND2A", Microbiol Spectr., e0378523, PMID: 38240571, DOI: 10.1128/spectrum.03785-23 (link)
  6. Luganini, A., et al., (2023), "Mechanisms of antiviral activity of the new hDHODH inhibitor MEDS433 against respiratory syncytial virus replication", Antiviral Res., 105734, PMID: 37852322, DOI: 10.1016/j.antiviral.2023.105734 (link)
  7. Sugimoto, A. et al., (2023), "Identification of novel lactic acid bacteria with enhanced protective effects against influenza virus", PLoS One, 18(8):e0273604, PMID: 37556447, DOI: 10.1371/journal.pone.0273604 (link)
  8. Killarney, S. et al., (2023), "Executioner caspases restrict mitochondrial RNA-driven Type I IFN induction during chemotherapy-induced apoptosis", Nat. Commun. 14(1):1399, PMID: 36918588, DOI: 10.1038/s41467-023-37146-z (link)
  9. Dowling, D.J. et al., (2022), "development of a TLR7/8 agonist adjuvant formulation to overcome early life hyporesponsiveness to DTaP vaccination", Sci. Rep. 12(1):16860, PMID: 36258023, DOI: 10.1038/s41598-022-20346-w (link)

 

 

Background Literature:

  1. Staehelin et al. (1981) "A Rapid Quantitative Assay of High Sensitivity for Human Leukocyte Interferon with Monoclonal Antibodies" in Methods in Enzymology, Vol. 79 (Pestka, ed.), Academic Press, New York, 589-595.
  2. Kelder et al. (1986) "A Sandwich Radioimmunoassay for Human IFNa" in Methods in Enzymology, Vol. 119 (Pestka, ed.), Academic Press, New York, 582-587.
  3. Human IFN-α international reference standard provided by the NIH, reference no. Gxa01-901-535. Pestka (1986) "Interferon Standards and General Abbreviations" in Methods in Enzymology, Vol. 119 (Pestka, ed.), Academic Press, New York, 14-23.
  4. Rubinstein et al. (1981) "Human Leukocyte Interferon: Isolation and Characterization of Several Molecular Forms," Arch. Biochem. Biophys. 210, 307-318.
  5. Hobbs et al. (1982) "Purification and Characterization of Interferons from a Continuous Myeloblastic Cell Line," J. Biol. Chem. 257, 4071-4076.

Documentation

Certificate of Analysis (CoA), Protocol, Safety Data Sheet (SDS), and Technical Data Sheet (TDS)
41135 CoA & Protocol

41135-1 Certificate of Analysis & Protocol

41135 TDS

41135 Technical Data Sheet

41135 SDS

41135 Safety Data Sheet

41135 Protocol

41135 Protocol (Full)

41135 Product Flyer

41135 Product Flyer